Clinical research in Southeast Asia, as well as positioning for product registration and commercialization, is increasingly central to multinational drug development programs.
Toronto, Canada (PRWEB) May 28, 2013
Clinical research in Southeast Asia, as well as positioning for product registration and commercialization, is increasingly central to multinational drug development programs. The S.E. Asia region combines many of the elements western sponsors require, including: vibrant urban healthcare systems, English as the primary business language, first-rate medical credentials of Investigators, and progressive regulatory conditions to ensure quality data and patient safety.
Commercialization is key and Southeast Asia is an ideal place for it. Home to 60% of the world’s population and growing rapidly, this region is expected to exceed a population of 5.6 billion by 2050. It has been anticipated that S.E. Asia’s pharmaceutical and device market could reach a size of $20B by 2015, becoming one of the top 10 drug markets in the world.
The S.E. Asia region offers a venue for faster recruitment and more cost effective trials in addition to rapidly growing markets for product registration and commercialization to the over 1.5B population size.
Join us for this live event, with experts from Max Neeman, as we discuss:
- Clinical research scenario in S.E. Asia
- Market opportunity, registration
- New regulatory & safety guidelines
To learn more about the event, visit:
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx
Karen Lim (416) 977-6555 ext 227